Deborah Hinnen

Summary

Publications

  1. ncbi The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus
    Debbie Hinnen
    Mid America Diabetes Associates, Wichita, Kansas 67226, USA
    J Cardiovasc Nurs 28:157-65. 2013
  2. ncbi The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with Type 2 Diabetes: design of the Structured Testing Program (STeP) study, a cluster-randomised, clinical trial [NCT00674986]
    William Polonsky
    University of California, San Diego, and Behavioral Diabetes Institute, San Diego, California 92150, USA
    BMC Fam Pract 11:37. 2010
  3. ncbi Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes
    Deborah Hinnen
    Mid America Diabetes Associates, Wichita, KS 67211, USA
    J Am Board Fam Med 19:612-20. 2006
  4. ncbi Cardiovascular event prevention in the person with type 2 diabetes: case examples for identifying and treating multiple risks
    Ashok Balasubramanyam
    Baylor College of Medicine, One Baylor Plaza, Room 719E, Houston, TX 77030, USA
    Diabetes Educ 32:163S-173S; quiz 174S-177S. 2006

Collaborators

Detail Information

Publications4

  1. ncbi The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus
    Debbie Hinnen
    Mid America Diabetes Associates, Wichita, Kansas 67226, USA
    J Cardiovasc Nurs 28:157-65. 2013
    ..Recently, there has been renewed interest in the role that the kidney plays in glucose homeostasis and the potential of the kidney as a therapeutic target in T2DM...
  2. ncbi The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with Type 2 Diabetes: design of the Structured Testing Program (STeP) study, a cluster-randomised, clinical trial [NCT00674986]
    William Polonsky
    University of California, San Diego, and Behavioral Diabetes Institute, San Diego, California 92150, USA
    BMC Fam Pract 11:37. 2010
    ..We have designed an SMBG intervention study that attempts to address these issues...
  3. ncbi Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes
    Deborah Hinnen
    Mid America Diabetes Associates, Wichita, KS 67211, USA
    J Am Board Fam Med 19:612-20. 2006
    ..The use of these agents may provide an opportunity to bring about new improvements in diabetes care...
  4. ncbi Cardiovascular event prevention in the person with type 2 diabetes: case examples for identifying and treating multiple risks
    Ashok Balasubramanyam
    Baylor College of Medicine, One Baylor Plaza, Room 719E, Houston, TX 77030, USA
    Diabetes Educ 32:163S-173S; quiz 174S-177S. 2006